Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 107Specimen Handling 86pembrolizumab 80enzalutamide 64Nivolumab 62Gemcitabine 58Docetaxel 51Androgen Antagonists 44Abiraterone Acetate 44apalutamide 43Radiosurgery 42Prednisone 42darolutamide 40Cisplatin 38Biopsy 36Radiotherapy 33cabozantinib 32Carboplatin 30abiraterone 29Ipilimumab 29Pluvicto 27durvalumab 25Leuprolide 24enfortumab vedotin 23X-Rays 23Radiation 23olaparib 20Standard of Care 20avelumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pirarubicin × Genitourinary × 90 days × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡